Human Immunoglobulin G
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Human Immunoglobulin G
- Human Immunoglobulin G: From Immune Globulin Therapy to Severe Nonproliferative Diabetic Retinopathy
Human Immunoglobulin G: From Immune Globulin Therapy to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Human immunoglobulin G is a plasma-derived antibody product that is registered and marketed in Singapore as an injection, although the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, with a very high model score. Currently there are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text is blank in the registration record) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Human immunoglobulin G is a pooled plasma-derived antibody product. Its original approved indication could not be identified from the Singapore registration record, so the link between its established use and the predicted new indication cannot be assessed.
One speculative idea is that immunoglobulin may modulate inflammatory pathways involved in diabetic microvascular disease. No trial or publication in the data compiled for this report supports this, and the high TxGNN score reflects a computational prediction only.
Other top predictions from the model include diabetic retinopathy (99.63%), drug-induced osteoporosis (99.37%), diabetic cataract (98.87%) and several other cataract types (about 97.6–97.9%). Several cataract terms share identical scores, which suggests a shared knowledge-graph signal rather than disease-specific evidence. None of these has any registered trials or literature in the compiled data.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16766P | IMMUNOGLOBULINS SG INJECTION 50mg/ml (SK Plasma Co., Ltd.) | Injection | Not stated in the registration record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score. There are no clinical trials or publications, the mechanism of action is unknown, and the original indication and safety labelling are missing from the compiled data. This does not allow a meaningful benefit-risk assessment.
To proceed, the following is needed:
- The Singapore package insert (approved indications, warnings, contraindications), which is required before any safety screening
- Mechanism of action data for the product
- A literature and trial search specific to immunoglobulin in diabetic retinopathy
- An assessment of route compatibility, since the product is a systemic injection and eye disease may need a different route of delivery
- A review of whether the predicted indications are plausible, given that the identical cataract scores look like a graph artifact
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.